Year All202420232022202120202019 Apr 02, 2024 Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 Apr 01, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 01, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 28, 2024 Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences Feb 27, 2024 Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates Feb 13, 2024 Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference Feb 01, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 25, 2024 Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments Jan 08, 2024 Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform Jan 02, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 02, 2024 Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Apr 01, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 01, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 27, 2024 Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Feb 13, 2024 Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
Feb 01, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 08, 2024 Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
Jan 02, 2024 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)